118 related articles for article (PubMed ID: 38247288)
1. Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma.
Lin J; Chen Y; Zhang Z; Qi F; Zhang M
Environ Toxicol; 2024 May; 39(5):2717-2731. PubMed ID: 38247288
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma.
Sun M; Qi S; Wu M; Xia W; Xiong H
Front Genet; 2022; 13():909556. PubMed ID: 36338983
[No Abstract] [Full Text] [Related]
3. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract][Full Text] [Related]
4. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
6. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
Song C; Shang F; Tu W; Liu X
BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
8. Effect of activating cancer-associated fibroblasts biomarker TNC on immune cell infiltration and prognosis in breast cancer.
Huang T; Lu C; Zhang Y; Lin BY; Zhang ZJ; Zhu D; Wang L; Lu Y
Ann Med; 2023; 55(2):2250987. PubMed ID: 38375814
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S
Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570
[TBL] [Abstract][Full Text] [Related]
10. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
[TBL] [Abstract][Full Text] [Related]
11. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
13. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
[No Abstract] [Full Text] [Related]
14. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment.
Zhu Z; Ye W; Wu X; Lin S; Xu J; Li L; Li J; Wang H; Huang Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33350431
[TBL] [Abstract][Full Text] [Related]
16. THEM6 is a prognostic biomarker for breast cancer and is associated with immune infiltration.
Lu X; Chen W; Tian G; Ge F
Sci Rep; 2023 Dec; 13(1):21974. PubMed ID: 38081884
[TBL] [Abstract][Full Text] [Related]
17. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
[TBL] [Abstract][Full Text] [Related]
18. Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation.
Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N
Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491
[TBL] [Abstract][Full Text] [Related]
19. Mining the prognostic significance and immune infiltration of
Zhou Y; Jiang S; Yu S; Zhu L; Liu Y; Li S; Hao N; Ren Y
Gland Surg; 2022 Apr; 11(4):720-741. PubMed ID: 35531108
[TBL] [Abstract][Full Text] [Related]
20. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]